Swine Vaccines Market Report 2026

Swine Vaccines Market Overview

• Swine Vaccines market size has reached to $2.37 billion in 2025 • Expected to grow to $3.74 billion in 2030 at a compound annual growth rate (CAGR) of 9.6% • Growth Driver: Rising Prevalence Of Swine Diseases Fuels Growth In Swine Vaccine Market • Market Trend: Innovative Advances In Swine Vaccination • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Swine Vaccines Market?

The swine vaccine refers to a preparation that is administered or injected in pigs to stimulate the immune response against a specific infectious agent. These vaccines are crucial for preventing diseases that can significantly impact pig health, productivity, and overall herd management. The main product types of swine vaccines are attenuated live vaccines, inactivated vaccines, subunit vaccines, DNA (deoxyribonucleic acid) vaccines, and recombinant vaccines. Attenuated live vaccines are made up of living viruses or bacteria that have undergone a process to weaken (attenuate) and diminish their pathogenicity. The attenuated live vaccine is a swine vaccine used to administer in pigs to multiply within the body to trigger a stronger antigenic stimulus, which results in long-lasting immunity. The diseases indicated are viral infections, bacterial infections, parasitic infections, fungal infections, and others. It is distributed through veterinary hospitals, veterinary pharmacies, and online pharmacies, which are provided through government tenders and market sales.

What Is The Swine Vaccines Market Growth Forecast?

The swine vaccines market size is expected to see strong growth in the next few years. It will grow to $3.74 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to adoption of dna and recombinant vaccines, increasing government support for swine vaccination programs, growth in precision livestock farming, focus on emerging infectious diseases, expansion of cold-chain infrastructure for vaccine distribution. Major trends in the forecast period include development of multi-valent swine vaccines, focus on preventive swine healthcare, advancements in dna and recombinant vaccines, cold-chain optimized vaccine distribution, rapid response vaccines for emerging swine diseases.

Global Swine Vaccines Market Segmentation

1) By Product: Attenuated Live Vaccines, Inactivated Vaccines, Subunit Vaccines, Deoxyribonucleic Acid (DNA) Vaccines, Recombinant Vaccines 2) By Disease: Viral Infections, Bacterial Infections, Parasitic Infection, Fungal Infections, Other Diseases 3) By Distribution Channel: Veterinary Hospitals, Veterinary Pharmacies, Online Pharmacies 4) By Application: Government Tender, Market Sales Subsegments: 1) By Attenuated Live Vaccines: Live Attenuated Virus Vaccines, Live Attenuated Bacterial Vaccines 2) By Inactivated Vaccines: Whole Inactivated Virus Vaccines, Inactivated Bacterial Vaccines 3) By Subunit Vaccines: Protein Subunit Vaccines, Polysaccharide Subunit Vaccines 4) By Deoxyribonucleic Acid (DNA) Vaccines: Plasmid DNA Vaccines, Nucleic Acid Vaccines 5) By Recombinant Vaccines: Recombinant Vector Vaccines, Recombinant Protein Vaccines

What Is The Driver Of The Swine Vaccines Market?

The rising prevalence of diseases in swine is expected to propel the swine vaccine market going forward. Swine disease is any divergence from an organism's normal structural or functional condition accompanied by a few signs and symptoms of diseases such as pseudorabies, influenza. Diseases in swine are rising because intensive farming practices increase animal density, which accelerates disease transmission and makes outbreaks harder to control. Swine vaccines effectively combat the rising prevalence of diseases in swine by stimulating the immune system to recognize and respond to specific pathogens, thereby reducing infection rates, mitigating disease severity, and promoting overall herd health. For instance, in December 2023, according to the Swine Health Information Center, a US-based non-profit organization, in Poland, there has been a troubling increase in cases of African Swine Fever (ASF) among wild boars. As of early 2023, the country has recorded 2,347 confirmed ASF cases in wild boars, exceeding the total from 2022. Therefore, the rising prevalence of diseases in swine is expected to drive the growth of the market.

Key Players In The Global Swine Vaccines Market

Major companies operating in the swine vaccines market are Merck & Co Inc., Boehringer Ingelheim Animal Health USA Inc., Elanco Animal Health Inc., Biogenesis Bago SA, Phibro Animal Health Corporation, KM Biologics Co. Ltd., Hipra Laboratories SA, Ceva Santé Animale SA, Zoetis Inc., Jinyu Bio-Technology Co. Ltd., China Animal Husbandry Industry Co. Ltd., Virbac SA, Harbin Veterinary Research Institute, Bioveta AS, Bimeda Holdings PLC, Biovac Ltd., Hester Biosciences Limited, Hygieia Biological Laboratories, IDT Biologika GmbH, Intervet Inc., Komipharm International Co. Ltd., Kyoritsu Seiyaku Corporation, Lohmann Animal Health International, Norbrook Laboratories Limited, Ouro Fino Saúde Animal SA, Prondil SA, Vaxxinova International BV, Vetoquinol SA, Veyx Pharma GmbH, Tianjin Ringpu Bio-Technology Co. Ltd.

Global Swine Vaccines Market Trends and Insights

Major companies operating in the swine vaccine market are increasing their focus on introducing innovative vaccines, such as Circumvent CML, to gain a competitive edge. Circumvent CML is a vaccine designed to protect swine herds against diseases, enhancing overall swine health and productivity. For instance, in June 2023, Merck Animal Health, a US-based pharmaceutical company, launched a new 3-in-one swine vaccine called Circumvent CML, which controls for the diseases Porcine Circovirus Type 2a (PCV-2a), Porcine Circovirus Type 2d (PCV-2d), Mycoplasma hyopneumoniae, and Lawsonia intracellularis. This new vaccine is built on Merck's foundation of tried-and-true, proven antigens and adjuvant systems that have been available in Circumvent PCV-M G2 and their standalone product, Porcilis Ileitis.

What Are Latest Mergers And Acquisitions In The Swine Vaccines Market?

In July 2024, MSD Animal Health, a US-based biopharmaceutical company, acquired Elanco’s aqua business for $1.3 billion. This acquisition MSD Animal Health aim is to significantly enhance its position in the aquaculture industry by expanding its portfolio of products and solutions aimed at promoting fish health, welfare, and sustainability. Elanco is a US-based pharmaceutical company, that specializes in providing swine vaccine solutions.

Regional Outlook

North America was the largest region in the swine vaccines market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Swine Vaccines Market?

The swine vaccine market consists of sales of haemophilus parasuis, pasteurella, salmonella, and streptococcus suis. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.